Pegvaliase-pqpz (Palynziq) — CPB 0933 | AETNA Coverage Update

Aetna modified CPB 0933 for pegvaliase-pqpz (Palynziq), effective September 26, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its Palynziq coverage policy under CPB 0933 Aetna system, setting specific blood phenylalanine thresholds that determine both initial approval and continuation of therapy. The primary codes tied to this policy are CPT 84030 (phenylalanine blood test), CPT 96372 (subcutaneous injection), and ICD-10 E70.0 (classical phenylketonuria). If your practice bills for PKU management or specialty infusion services, this update directly affects your documentation requirements and your risk of claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Pegvaliase-pqpz (Palynziq)
Policy Code	CPB 0933
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Metabolic disease, medical genetics, PKU management
Key Action	Document baseline blood phenylalanine concentration (CPT 84030) before initiating therapy and at each continuation review

---

Aetna Palynziq Coverage Criteria and Medical Necessity Requirements 2025

The real issue with this Aetna Palynziq coverage policy is that medical necessity lives or dies on a single lab value: blood phenylalanine concentration. Get that lab documented correctly or your claim gets denied. It's that straightforward.

For initial approval, Aetna requires two things. The member must be 18 years of age or older. And baseline blood phenylalanine concentration—measured before the first dose—must exceed 600 micromol/L. Both criteria must be met. Missing either one kills the authorization.

Aetna specifies the prescriber must be experienced in PKU management. That's not a formality. If your prescribing provider doesn't have documented specialty experience in phenylketonuria, document it proactively. A claim denial at prior authorization is harder to recover than one you prevent.

Initial Approval: What You Need in the Chart

Before you submit a prior authorization for Palynziq under CPB 0933, the medical record must show:

#	Covered Indication Copy
1	Age verification — member is 18 or older
2	Baseline phenylalanine lab — CPT 84030 result showing >600 micromol/L, drawn before treatment starts
3	Prescriber credentials — evidence of PKU management experience

If the member is currently on Kuvan (sapropterin), Aetna expects a transition plan. The policy specifies Kuvan will be discontinued after an appropriate overlap period. Document that transition explicitly in the chart. Do not bill both medications as ongoing concurrent therapy once Palynziq is established.

Continuation of Therapy: The "Either/Or" Framework

This is where the policy gets operationally complex. Aetna's continuation criteria use an either/or structure. Your billing team needs to understand both branches.

Branch 1: The member achieved a response. Blood phenylalanine concentration is at or below 600 micromol/L. This is the clean path—document the lab, continue therapy, bill with confidence.

Branch 2: The member has not yet hit 600 micromol/L, but continuation is still medically necessary under one of two sub-conditions:

#	Covered Indication Copy
1	The member hasn't been titrated to the maximum dose of 60 mg once daily yet, or
2	The member has received fewer than 16 weeks of continuous treatment at the 60 mg maximum dose

This is a reasonable framework, but it requires precise tracking. You need to document the current dose, the duration at that dose, and whether the phenylalanine threshold has been met at every continuation review. A vague note saying "therapy is ongoing" won't satisfy a medical necessity audit.

The real issue here is that continuation reimbursement depends on your team knowing exactly where the member is in the titration sequence. Is the patient at 20 mg daily? 40 mg? 60 mg? How many weeks at max dose? These aren't clinical questions at authorization time—they're billing questions. Your charge capture workflow needs to pull this data.

Dosing Milestones That Trigger Coverage Decisions

The dosing ladder matters for medical necessity documentation at each step:

#	Covered Indication Copy
1	20 mg once daily — standard titration target; requires at least 24 continuous weeks before escalating
2	40 mg once daily — escalation option if 20 mg fails to achieve ≤600 micromol/L; requires at least 16 continuous weeks before further escalation
3	60 mg once daily — maximum dose; if no adequate response after 16 continuous weeks at this dose, Aetna expects discontinuation

Document the duration at each dose level. This is what supports continuation prior auth at each renewal cycle.

---

Aetna Palynziq Exclusions and Non-Covered Indications

Aetna is explicit: all indications for pegvaliase-pqpz other than PKU in adults with phenylalanine concentration above 600 micromol/L are considered experimental, investigational, or unproven.

That means off-label use doesn't get covered. No exceptions are carved out in this policy. If someone submits a Palynziq claim for a member under 18, or for a member with a baseline phenylalanine below 600 micromol/L, expect denial.

The concomitant use restriction also matters here. Aetna will not cover Palynziq and Kuvan used together on an ongoing basis. The policy allows a brief overlap period during transition, but once that's done, the two drugs should not be billed as concurrent active therapies. A claim showing both active simultaneously—without documentation of a transition—is a denial waiting to happen.

---

Coverage Indications at a Glance

---

Aetna Palynziq Billing Guidelines and Action Items 2025

Here's what your billing team needs to do before and after the September 26, 2025 effective date.

1. Audit all active Palynziq prior authorizations now.
Pull every member currently on Palynziq. For each one, confirm the chart has a documented baseline phenylalanine result from CPT 84030 showing >600 micromol/L. If a prior auth was approved without that lab clearly documented, get it added to the record before the next renewal.

2. Build a dose-and-duration tracker into your workflow.
Every continuation auth submission needs to show the current dose (20 mg, 40 mg, or 60 mg), how many continuous weeks the member has been at that dose, and the most recent phenylalanine lab result. Build this into your prior auth template now. Don't wait for a denial to force it.

3. Check for concurrent Kuvan billing.
Run a claim history check for any member being billed for both Palynziq and Kuvan. If concurrent billing exists beyond an active transition window, correct it. Ongoing concurrent billing conflicts directly with this coverage policy and will trigger denial or recoupment.

4. Confirm the prescriber specialty is documented.
Palynziq billing requires the prescriber to have PKU management experience. Make sure the ordering provider's specialty and relevant experience are in the medical record. This is an audit target—document it once and keep it current.

5. Set continuation review alerts at the 16-week and 24-week marks.
The policy's dose escalation thresholds are time-based. At 24 continuous weeks on 20 mg, the member becomes eligible for escalation to 40 mg. At 16 continuous weeks on 40 mg, escalation to 60 mg is possible. And at 16 continuous weeks on 60 mg with no response, discontinuation is expected. Flag these dates in your system. Missed timelines mean denied continuations.

6. Link ICD-10 E70.0 to every claim.
Classical phenylketonuria (E70.0) is the only covered diagnosis under this policy. Every claim for CPT 96372 (the subcutaneous injection administration code) and CPT 84030 (the phenylalanine lab) must link to E70.0. A mismatched or missing diagnosis code is an easy denial that has nothing to do with clinical care.

If your population includes edge cases—patients near the 600 micromol/L threshold, patients approaching 16 weeks at max dose, or patients transitioning off Kuvan—loop in your compliance officer before the September 26, 2025 effective date. The criteria are clear in the aggregate, but individual cases can get complicated fast.

---

CPT, HCPCS, and ICD-10 Codes for Pegvaliase-pqpz (Palynziq) Under CPB 0933

CPT Codes Associated with This Policy

Code	Type	Description Copy
84030	CPT	Phenylalanine (PKU), blood
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
E70.0	Classical phenylketonuria

A note on CPT 96372: This is the administration code for the subcutaneous injection. Palynziq is a self-administered or provider-administered subcutaneous injection, so 96372 applies to the injection visit. Make sure your charge capture pairs 96372 with the drug's J-code (not listed in this policy document—confirm the current J-code for pegvaliase-pqpz with your drug vendor or specialty pharmacy) and with E70.0.

A note on CPT 84030: This lab code is the documentation backbone for this entire policy. Initial approval requires it before therapy starts. Continuation approval requires it at each review. Without a clean CPT 84030 result tied to the right date in the medical record, your prior auth doesn't have legs.

---